Avidity Biosciences (RNA) Stock Forecast & Price Target

Compare

1,099 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RNA Analyst Ratings

Hold

3 Buy

11 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Avidity

Biosciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RNA Stock 12 Month Forecast

Average Price Target

$73.69

▲(2.15% Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Avidity Biosciences in the last 3 months. The average price target is $73.69 with a high forecast of $96.00 and a low forecast of $65.00. The average price target represents a 2.15% change from the last price of $72.14.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"$25","43":"$43","61":"$61","79":"$79","97":"$97"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":96,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$96.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":73.69,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$73.69</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$65.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,43,61,79,97],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,71.35,73.24615384615385,75.14230769230768,77.03846153846153,78.93461538461538,80.83076923076922,82.72692307692307,84.62307692307692,86.51923076923077,88.41538461538461,90.31153846153846,92.2076923076923,94.10384615384615,{"y":96,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,71.35,71.53,71.71,71.89,72.07,72.25,72.42999999999999,72.61,72.78999999999999,72.97,73.14999999999999,73.33,73.50999999999999,{"y":73.69,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,71.35,70.86153846153846,70.37307692307692,69.88461538461539,69.39615384615384,68.9076923076923,68.41923076923077,67.93076923076923,67.4423076923077,66.95384615384616,66.46538461538461,65.97692307692307,65.48846153846154,{"y":65,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":41.3,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.08,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.93,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.64,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.74,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.69,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.17,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.46,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.92,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.23,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.85,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.35,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$96.00

Average Price Target$73.69

Lowest Price Target$65.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Gavin Clark-Gartner

Evercore ISI

$65→$72

Hold

-0.19%

Downside

Downgraded

12/18/25

Avidity Biosciences downgraded to In Line from Outperform at Evercore ISIAvidity Biosciences downgraded to In Line from Outperform at Evercore ISI

Boobalan Pachaiyappan

Roth MKM

$72

Hold

-0.19%

Downside

Reiterated

12/18/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Novan (NASDAQ: NOVN), Avidity Biosciences (NASDAQ: RNA) and Insmed (NASDAQ: INSM)

William Pickering

Bernstein

$72

Hold

-0.19%

Downside

Reiterated

11/25/25

Bernstein Sticks to Its Hold Rating for Avidity Biosciences (RNA)

Eric Schmidt FCA

Cantor Fitzgerald

$96

Buy

33.07%

Upside

Reiterated

11/18/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Avidity Biosciences (RNA)

Yanan Zhu

Wells Fargo

$75

Buy

3.96%

Upside

Reiterated

11/13/25

Analysts Are Bullish on Top Healthcare Stocks: Centessa Pharmaceuticals (CNTA), Legend Biotech (LEGN)

Geoff Meacham

Citi

$72

Hold

-0.19%

Downside

Reiterated

11/12/25

Analysts Offer Insights on Healthcare Companies: HCA Healthcare (NYSE: HCA), Avidity Biosciences (NASDAQ: RNA) and Cross Country Healthcare (NASDAQ: CCRN)

Ritu Baral

TD Cowen

$74

Hold

2.58%

Upside

Reiterated

11/11/25

Hold Rating on Avidity Biosciences Amid Novartis Acquisition and Strategic Developments

Joseph Stringer

Needham

Hold

―

Reiterated

11/11/25

Hold Rating on Avidity Biosciences Amid Novartis Acquisition Uncertainty

Luca Issi

RBC Capital

$72

Hold

-0.19%

Downside

Reiterated

11/10/25

Avidity Biosciences (RNA) Receives a Hold from RBC Capital

Keay Nakae

Chardan Capital

$72

Hold

-0.19%

Downside

Reiterated

11/07/25

Chardan Capital Reaffirms Their Hold Rating on Avidity Biosciences (RNA)

Joseph Schwartz

Leerink Partners

$65→$72

Hold

-0.19%

Downside

Downgraded

10/27/25

Avidity Biosciences downgraded to Market Perform from Outperform at LeerinkAvidity Biosciences downgraded to Market Perform from Outperform at Leerink

Ananda Ghosh

H.C. Wainwright

$87→$72

Hold

-0.19%

Downside

Downgraded

10/27/25

Avidity Biosciences downgraded to Neutral from Buy at H.C. WainwrightAvidity Biosciences downgraded to Neutral from Buy at H.C. Wainwright

Martin Auster

Raymond James

$72

Hold

-0.19%

Downside

Downgraded

10/27/25

Avidity Biosciences (RNA) was downgraded to a Hold Rating at Raymond James

Tazeen Ahmad

Bank of America Securities

$65

Buy

-9.90%

Downside

Reiterated

10/13/25

Avidity Biosciences: Strategic Progress and Promising Clinical Data Drive Buy Rating

Corinne Johnson

Goldman Sachs

$53

Buy

-26.53%

Downside

Assigned

09/10/25

Avidity Biosciences: Promising Outlook for DMD Treatment with Del-Zota and Platform Expansion

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Gavin Clark-Gartner

Evercore ISI

$65→$72

Hold

-0.19%

Downside

Downgraded

12/18/25

Avidity Biosciences downgraded to In Line from Outperform at Evercore ISIAvidity Biosciences downgraded to In Line from Outperform at Evercore ISI

Boobalan Pachaiyappan

Roth MKM

$72

Hold

-0.19%

Downside

Reiterated

12/18/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Novan (NASDAQ: NOVN), Avidity Biosciences (NASDAQ: RNA) and Insmed (NASDAQ: INSM)

William Pickering

Bernstein

$72

Hold

-0.19%

Downside

Reiterated

11/25/25

Bernstein Sticks to Its Hold Rating for Avidity Biosciences (RNA)

Eric Schmidt FCA

Cantor Fitzgerald

$96

Buy

33.07%

Upside

Reiterated

11/18/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Avidity Biosciences (RNA)

Yanan Zhu

Wells Fargo

$75

Buy

3.96%

Upside

Reiterated

11/13/25

Analysts Are Bullish on Top Healthcare Stocks: Centessa Pharmaceuticals (CNTA), Legend Biotech (LEGN)

Geoff Meacham

Citi

$72

Hold

-0.19%

Downside

Reiterated

11/12/25

Analysts Offer Insights on Healthcare Companies: HCA Healthcare (NYSE: HCA), Avidity Biosciences (NASDAQ: RNA) and Cross Country Healthcare (NASDAQ: CCRN)

Ritu Baral

TD Cowen

$74

Hold

2.58%

Upside

Reiterated

11/11/25

Hold Rating on Avidity Biosciences Amid Novartis Acquisition and Strategic Developments

Joseph Stringer

Needham

Hold

―

Reiterated

11/11/25

Hold Rating on Avidity Biosciences Amid Novartis Acquisition Uncertainty

Luca Issi

RBC Capital

$72

Hold

-0.19%

Downside

Reiterated

11/10/25

Avidity Biosciences (RNA) Receives a Hold from RBC Capital

Keay Nakae

Chardan Capital

$72

Hold

-0.19%

Downside

Reiterated

11/07/25

Chardan Capital Reaffirms Their Hold Rating on Avidity Biosciences (RNA)

Joseph Schwartz

Leerink Partners

$65→$72

Hold

-0.19%

Downside

Downgraded

10/27/25

Avidity Biosciences downgraded to Market Perform from Outperform at LeerinkAvidity Biosciences downgraded to Market Perform from Outperform at Leerink

Ananda Ghosh

H.C. Wainwright

$87→$72

Hold

-0.19%

Downside

Downgraded

10/27/25

Avidity Biosciences downgraded to Neutral from Buy at H.C. WainwrightAvidity Biosciences downgraded to Neutral from Buy at H.C. Wainwright

Martin Auster

Raymond James

$72

Hold

-0.19%

Downside

Downgraded

10/27/25

Avidity Biosciences (RNA) was downgraded to a Hold Rating at Raymond James

Tazeen Ahmad

Bank of America Securities

$65

Buy

-9.90%

Downside

Reiterated

10/13/25

Avidity Biosciences: Strategic Progress and Promising Clinical Data Drive Buy Rating

Corinne Johnson

Goldman Sachs

$53

Buy

-26.53%

Downside

Assigned

09/10/25

Avidity Biosciences: Promising Outlook for DMD Treatment with Del-Zota and Platform Expansion

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Avidity Biosciences

1 Month

xxx

Success Rate

18/28 ratings generated profit

Average Return

+7.11%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 64.29% of your transactions generating a profit, with an average return of +7.11% per trade.

3 Months

xxx

Success Rate

18/28 ratings generated profit

Average Return

+28.26%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +28.26% per trade.

1 Year

Tazeen AhmadBank of America Securities

Success Rate

11/11 ratings generated profit

Average Return

+89.07%

reiterated a buy rating 2 months ago

Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +89.07% per trade.

2 Years

xxx

Success Rate

11/11 ratings generated profit

Average Return

+95.10%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +95.10% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RNA Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RNA has received 8 Buy Ratings, 23 Hold Ratings, and 0 Sell Ratings. RNA average Analyst price target in the past 3 months is 73.69.

Each month's total comprises the sum of three months' worth of ratings.

RNA Financial Forecast

RNA Earnings Forecast

Next quarter’s earnings estimate for RNA is -$1.24 with a range of -$1.50 to -$0.61. The previous quarter’s EPS was -$1.27. RNA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year RNA has Performed in-line its overall industry.

RNA Sales Forecast

Next quarter’s sales forecast for RNA is $1.98M with a range of -$6.50M to $12.50M. The previous quarter’s sales results were $12.47M. RNA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year RNA has Performed in-line its overall industry.

RNA Stock Forecast FAQ

What is RNA’s average 12-month price target, according to analysts?

Based on analyst ratings, Avidity Biosciences Inc’s 12-month average price target is 73.69.

What is RNA’s upside potential, based on the analysts’ average price target?

Avidity Biosciences Inc has 2.15% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RNA a Buy, Sell or Hold?

Avidity Biosciences Inc has a consensus rating of Hold which is based on 3 buy ratings, 11 hold ratings and 0 sell ratings.

What is Avidity Biosciences Inc’s price target?

The average price target for Avidity Biosciences Inc is 73.69. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $96.00 ,the lowest forecast is $65.00. The average price target represents 2.15% Increase from the current price of $72.14.

What do analysts say about Avidity Biosciences Inc?

Avidity Biosciences Inc’s analyst rating consensus is a Hold. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of RNA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Avidity Biosciences (RNA) Stock Forecast & Price Target

RNA Analyst Ratings

RNA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Avidity Biosciences

RNA Analyst Recommendation Trends

RNA Financial Forecast

RNA Earnings Forecast

RNA Sales Forecast

RNA Stock Forecast FAQ

Detailed List of Analyst Forecasts